Alzheimer's disease
Conditions
Interventions
Control group:None
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Case group (1) Meet the Chinese guidelines for the diagnosis and treatment of dementia and cognitive impairment (2018) and the clinical diagnostic criteria for early AD and MCI developed by the National Institute of Aging (NIA) and the Alzheimer's Association (AA). The clinical diagnostic criteria of NIA-AA for early AD and MCI were established by the joint working group of the National Institute of Aging (NIA) and Alzheimer's Association (AA). 2) Memory impairment (self-reported or confirmed by an informed person) with a history of memory impairment of >3 months. 3) Montreal Cognitive Assessment Scale (MoCA) score of <26 (adjusted for years of education) and a Simple Mental State Examination Scale (MMSE) score of =19 (adjusted for years of education). Clinical Dementia Rating Scale (CDR) score of 0.5 or 1; Hachinski Index of Ischemia scale ? 4. 4) Age above 55 and below 80 years old, both sexes 5) voluntary participation of the patient and signed informed consent. 6) Right-handedness. Control group 1) no history of neurological or psychiatric disorders affecting cognition, such as stroke, depression, epilepsy, etc. 2) no significant physical deficits, such as vision or hearing loss, to complete the neuropsychological examination. 3) no significant infarcts or other types of lesions on routine brain imaging. 4) performance on objective cognitive function tests within normal limits and not meeting the diagnostic criteria for MCI. 5) MMSE score was normal (adjusted for years of education). CDR score was 0.
Exclusion criteria
Exclusion criteria: 1) Patients with cognitive impairment due to traumatic brain injury and intracranial tumors. 2) Parkinson's symptoms, prominent visual hallucinations and abnormalities of rapid eye movement sleep. 3) Patients with primary cardiovascular disease, liver, kidney and hematopoietic disorders and psychiatric disorders. 4) multiple vascular disease risk factors and/or extensive cerebrovascular lesions on brain imaging suggestive of vascular cognitive impairment. 5) prominent behavioral or language deficits early in the course of the disease that may suggest a degenerative frontotemporal lobe lesion. 6) rapid decline in cognitive function within weeks or months, usually suggestive of prion disease, tumor, or metabolic disease. 7) Patients with severe neurological dysfunction such as visual and hearing impairment. 8) those who have been dependent on alcohol or drugs for six months 9) Other known diseases that can affect cognitive function. 10) Those who are allergic to the study drug milli-needle needles, etc. 11) Those who are participating in other clinical trials. (12) Contraindications to MRI (including cardiac pacemakers, orthopedic implants and other metal implants; metal dentures greater than 2, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MRI; | — |
Countries
China
Contacts
Public ContactCheng Guanxun
Peking University Shenzhen Hospital
Outcome results
None listed